Biotech · Private company · Cambridge, MA, US
Cerevel Therapeutics, LLC
Track this companyFree. Adds Cerevel Therapeutics, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials220 recruiting or active
Pipeline programs35From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline35
- [11C]-carfentanilPhase 1 · Opioid Use DisorderClinicalTrials.gov · fetched Nov 12, 2026
- [11C]-LY2795050Phase 1 · Opioid Use DisorderClinicalTrials.gov · fetched Nov 12, 2026
- [14C]-darigabatPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- 10 mg CVL-231 as IR formulationPhase 1 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- 30 mg CVL-231 as fast release MR formulationPhase 1 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- 30 mg CVL-231 as medium release MR formulationPhase 1 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- 30 mg CVL-231 as slow-release MR formulationPhase 1 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- 30 mg CVL-231 Target Release, FastedPhase 1 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- 30 mg CVL-231 Target Release, FedPhase 1 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- CarbamazepinePhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- CarbamazepinePhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- CarbamazepinePhase 1 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- CVL-231Phase 1 · Blood PressureClinicalTrials.gov · fetched Nov 12, 2026
- CVL-231Phase 1 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- CVL-354Phase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- CVL-354Phase 1 · Opioid Use DisorderClinicalTrials.gov · fetched Nov 12, 2026
- CVL-751Phase 1 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- CVL-936Phase 1 · Substance Use Disorders (SUD)ClinicalTrials.gov · fetched Nov 12, 2026
- DarigabatPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- DarigabatPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- EmraclidinePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- EmraclidinePhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- EmraclidinePhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- EsomeprazolePhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- ItraconazolePhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- MetforminPhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- TavapadonPhase 1 · Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- TavapadonPhase 1 · Renal ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- TavapadonPhase 1 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Tavapadon [14C] suspensionPhase 1 · Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- Tavapadon tabletPhase 1 · Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- Treatment A: Emraclidine 30mg IR tablets (reference)Phase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- Treatment B: Emraclidine 30mg IR test tablets 1Phase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- Treatment C: Emraclidine 30mg IR test tablets 2Phase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- Treatment D: Emraclidine 30mg IR test tablets 3Phase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials22
- A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male ParticipantsPHASE1 · COMPLETED · started May 29, 2024ClinicalTrials.gov NCT06435923 · fetched Nov 12, 2026
- A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult ParticipantsPHASE1 · COMPLETED · started May 10, 2024ClinicalTrials.gov NCT06366243 · fetched Nov 12, 2026
- A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male ParticipantsPHASE1 · COMPLETED · started Mar 4, 2024ClinicalTrials.gov NCT06301971 · fetched Nov 12, 2026
- A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult ParticipantsPHASE1 · COMPLETED · started Aug 15, 2023ClinicalTrials.gov NCT05965219 · fetched Nov 12, 2026
- A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult ParticipantsPHASE1 · COMPLETED · started Jul 19, 2023ClinicalTrials.gov NCT05933187 · fetched Nov 12, 2026
- The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult ParticipantsPHASE1 · COMPLETED · started Jun 8, 2023ClinicalTrials.gov NCT05915546 · fetched Nov 12, 2026
- Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult ParticipantsPHASE1 · COMPLETED · started Apr 17, 2023ClinicalTrials.gov NCT05824143 · fetched Nov 12, 2026
- Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral DosingPHASE1 · COMPLETED · started Mar 2, 2023ClinicalTrials.gov NCT05547542 · fetched Nov 12, 2026
- Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's DiseasePHASE1 · COMPLETED · started Dec 15, 2022ClinicalTrials.gov NCT05610189 · fetched Nov 12, 2026
- Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult ParticipantsPHASE1 · COMPLETED · started Oct 19, 2022ClinicalTrials.gov NCT05581823 · fetched Nov 12, 2026
- To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal FunctionPHASE1 · COMPLETED · started May 10, 2022ClinicalTrials.gov NCT05404542 · fetched Nov 12, 2026
- To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic FunctionPHASE1 · COMPLETED · started Apr 29, 2022ClinicalTrials.gov NCT05404529 · fetched Nov 12, 2026
- Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With SchizophreniaPHASE1 · COMPLETED · started Jan 24, 2022ClinicalTrials.gov NCT05245539 · fetched Nov 12, 2026
- Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy ParticipantsPHASE1 · COMPLETED · started Dec 29, 2021ClinicalTrials.gov NCT05106309 · fetched Nov 12, 2026
- Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy ParticipantsPHASE1 · COMPLETED · started Nov 2, 2021ClinicalTrials.gov NCT05123079 · fetched Nov 12, 2026
- A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy ParticipantsPHASE1 · COMPLETED · started Oct 18, 2021ClinicalTrials.gov NCT05138653 · fetched Nov 12, 2026
- PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral DosingPHASE1 · COMPLETED · started Jun 1, 2021ClinicalTrials.gov NCT04787302 · fetched Nov 12, 2026
- A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for SchizophreniaPHASE2 · COMPLETED · started Mar 2, 2021ClinicalTrials.gov NCT04457310 · fetched Nov 12, 2026
- An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy SubjectsPHASE1 · COMPLETED · started Feb 4, 2020ClinicalTrials.gov NCT04241393 · fetched Nov 12, 2026
- A 2-Part Trial of CVL-751 in Subjects With Parkinson's DiseasePHASE1 · COMPLETED · started Jan 8, 2020ClinicalTrials.gov NCT04295642 · fetched Nov 12, 2026
- A Single Ascending Dose Trial of CVL-936 in Healthy SubjectsPHASE1 · TERMINATED · started Dec 16, 2019ClinicalTrials.gov NCT04232878 · fetched Nov 12, 2026
- A Multiple Ascending Dose Trial of CVL-231 in Subjects With SchizophreniaPHASE1 · COMPLETED · started Oct 15, 2019ClinicalTrials.gov NCT04136873 · fetched Nov 12, 2026
NIH awards1
- CVL-354, a kappa opioid receptor antagonist for treatment of opioid use disorder, withdrawal and relapseFiscal year 2024 · $2.7MNIH RePORTER 5UH3DA052166-03 · fetched Nov 12, 2026